NMN (nicotinamide mononucleotide) trials recruiting now
11 registrations that name NMN as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 11 registrations
Status
Phase
3US sites across 3 states
1
2 to 4
5 to 19
20 or more
All 11 registrations
RecruitingNCT07144527
Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
No phase
Scott Silveira
About 40 people
Started Feb 21, 2026
In plain words A study of NMN in people 60 to 80, run by Scott Silveira. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 60 to 80; healthy volunteers accepted. Conditions: Aging; Frailty; Exercise Tolerance; Healthy Male and Female Subjects.
Adults aged 60 to 80 years, of any sex
Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study
Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated by either: stress echocardiogram or coronary CT angiogram within the past 12 months showing normal left ventricular function, no…
Montreal Cognitive Assessment (MoCA) score of 26 or higher
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
NMN and TMG (Euexia); Nicotinamide Mononucleotide (NMN); Placebo
Registered summary
This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of nicotinamide mononucleotide (NMN) combined with trimethylglycine (TMG) supplementation, compared to NMN alone. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06882096
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
Phase 1
Metro International Biotech, LLC
About 32 people
Started Apr 28, 2025
In plain words A Phase 1 study of NMN in people 18 and older, run by Metro International Biotech, LLC. It plans to enroll about 32 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Healthy Adults.
A healthy, community-living, man or a woman between 18 and 40 years, inclusive or 65 years or older
Has a body mass index (BMI) between 19 and 35 kg/m2, inclusive
Is free from clinically significant medical problems as determined by the Investigator
Is capable of providing written informed consent.
1 more inclusion criterion and the exclusion criteria are on the listing.
We are doing this research to learn how healthy younger and older adults use two forms of vitamin B3-called nicotinamide mononucleotide (NMN) and nicotinamide (NAM)-to make NAD+. NAD+ is a natural substance that cells need for energy and other important processes. Our goal is to find out how these NAD precursors are absorbed and metabolized and how they raise NAD+ in different tissues. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07572825
Assessing the Safety and Tolerability of NMN in DHDDS-CDG
Phase 1
Eva Morava-Kozicz
About 8 people
Started May 8, 2026
In plain words A Phase 1 study of NMN in people 4 and older, run by Eva Morava-Kozicz. It plans to enroll about 8 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 4 and older. Conditions: DHDDS-Congenital Disorder of Glycosylation; DHDDS-CDG; Congenital Disorder of Glycosylation.
Subject is ≥ 4 years old
Subject has biologically and genetically proven heterozygous DHDDS-CDG.
Subject/legally authorized representative (LAR) is able to understand and provide written informed consent, and assent (as applicable) to participate in this study.
The exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Mononucleotide (NMN) Nucleosidase
Registered summary
The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol diphosphate synthase congenital disorder of glycosylation (DHDDS-CDG). This will to contribute to knowledge that will allow healthcare providers to make informed decisions about recommending this dietary supplement in this population.
Where, as registered
1 US site in 1 state.
RecruitingNCT06592859
Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People
No phase
People's Hospital of Quzhou
About 240 people
Started Aug 23, 2023
In plain words A study of NMN in people 39 to 70, run by People's Hospital of Quzhou. It plans to enroll about 240 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 39 to 70; healthy volunteers accepted. Conditions: Aging; NMN.
Local residents of Quzhou or living in Quzhou for over ten years.
age 40-50 and 60-70 years old, no major bad habits.
Gender unlimited.
in good health and has not undergone major surgery within half a year.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
NMN; placebo
Registered summary
This study is a single-center, randomized, double-blind, placebo-controlled clinical trial investigating a pharmacological intervention for aging. Its primary objective is to evaluate the efficacy of NMN while ensuring the safety of oral administration, with the aim of identifying effective strategies to delay aging and improve the quality of life in the elderly population. The main outcomes of this study are to characterize the patterns of NMN efficacy across different populations and to identify sensitive biomarkers that reflect responsiveness to the intervention.
Where, as registered
No US site; China (1).
RecruitingNCT06426355
The Effeciency of NMN in Improving IVF/ICSI-ET Pregnancy Outcomes in Patients With DOR
No phase
Peking University Third Hospital
About 200 people
Started Oct 1, 2023
In plain words A study of NMN in female participants 20 to 40, run by Peking University Third Hospital. It plans to enroll about 200 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 20 to 40. Conditions: Diminished Ovarian Reserve.
Individuals who are 20 to 40 years old.
At least two of the following three conditions should be met:
The concentrations of anti-Mullerian hormone < 1.1 ng/ml,
the values of antral follicle count was less than 7
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
NMN; Placebo
Registered summary
The purpose of the study is to understand the effect of nicotinamide mononucleotide (NMN) on patients with diminished ovarian reserve and the outcomes of IVF/ICSI-ET.
Where, as registered
No US site; China (1).
RecruitingNCT06991712
Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients
Phase 2
Christopher Kai Shun Leung
About 138 people
Started May 19, 2025
In plain words A Phase 2 study of NMN in people 18 and older, run by Christopher Kai Shun Leung. It plans to enroll about 138 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Glaucoma.
glaucoma patients
age ≥ 18 years
best corrected VA ≥20/40
IOP <21 mmHg
1 more inclusion criterion and the exclusion criteria are on the listing.
The goal of this clinical trial is to determine whether oral supplementation with different nicotinamide adenine dinucleotide (NAD) precursors can improve visual function in adults with primary open-angle glaucoma. The main questions it aims to answer are: 1. Does daily oral administration of equimolar doses of nicotinamide riboside (NR), nicotinamide (NAM), nicotinamide mononucleotide (NMN), or nicotinic acid (NA) improve visual field sensitivity in glaucoma patients over the short term? 2. The full summary is on the listing.
Where, as registered
No US site; Hong Kong (1).
RecruitingNCT06907329
The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.
No phase
Qing Su
About 126 people
Started Jun 5, 2025
In plain words A study of NMN in people 50 to 70, run by Qing Su. It plans to enroll about 126 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 70. Conditions: Immunosenescence; Metabolism.
Age 50-70 years with overweight or obesity (BMI 24kg/m2);
At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with HbA1c <7% without glucose-lowering drug therapy;
Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form.
The exclusion criteria are on the listing.
What it tests, as registered
NMN; Placebo
Registered summary
The ageing of our country is increasing and the ageing of the population has led to a significant increase in aging related diseases. During the aging process of the organism, cellular senescence can occur in all systems of the body, of which the senescence of the immune system is called immunosenescence. Some studies have shown that metabolic disorders can also trigger aging. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT06629636
Investigate the Efficacy of Using NMN to Improve Embryo Development Capacity.
No phase
Sunkaky Medical Cooperation
About 60 people
Started Aug 20, 2024
In plain words A study of NMN in female participants 32 to 42, run by Sunkaky Medical Cooperation. It plans to enroll about 60 people at 1 site, none in the US.
Having at least one previous embryo implantation failure
History of low Embryo quality at day3 or day5 (according to Veeck's and Gardner's Criteria)
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
NMN capsule; Placebo
Registered summary
The objective of this study is to investigate the efficacy of NMN supplementation in enhancing embryo developmental capacity and improving IVF success rates in patients experiencing IVF failures.
Where, as registered
No US site; Japan (1).
RecruitingNCT07451496
PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS)
No phase
National University of Singapore
About 20 people
Started Sep 29, 2025
In plain words A study of NMN in people 50 to 80, run by National University of Singapore. It plans to enroll about 20 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 80; healthy volunteers accepted. Conditions: Ageing.
Age 50-80 years (both male and female)
Relatively healthy and in stable health condition
Not engaged in regular resistance or aerobic training in the past 12 months (i.e., untrained)
VO₂peak below the 75th percentile for age- and sex-specific norms
6 more inclusion criteria and the exclusion criteria are on the listing.
As the population ages, the growing prevalence of age-related diseases is creating substantial challenges for healthcare systems worldwide. Current therapeutic strategies often target individual diseases and decrease mortality without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process itself could prevent, delay, or manage the severity of multiple age-related diseases concurrently, thereby improving overall healthspan and reducing healthcare burdens. The full summary is on the listing.
Where, as registered
No US site; Singapore (1).
Not yet recruitingNCT07880925
Effects of Trigonelline Monohydrate on NAD+ Metabolism, Pharmacokinetics, Safety, and Tolerability in Healthy Adults
Phase 1
dsm-firmenich Switzerland AG
About 60 people
Starts Oct 2026 (estimated)
In plain words A Phase 1 study of NMN in people 40 to 70, run by dsm-firmenich Switzerland AG. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 70; healthy volunteers accepted. Conditions: NAD+ Metabolism; Pharmacokinetics; Bioavailability; Healthy Adults.
Adults who are 40 to 70 years of age (inclusive) at the time of signing the informed consent.
Are able to consume study product capsules whole without chewing.
Have suitable veins for repeated venipuncture.
Non-smokers (including nicotine vaping) and have not used any nicotine products (patches, gums, etc.) for > 3 months prior to Visit 2.
10 more inclusion criteria and the exclusion criteria are on the listing.
This Phase 1 study is designed to evaluate the pharmacokinetic, pharmacodynamic, bioavailability, safety, and tolerability effects of trigonelline monohydrate in generally healthy adults aged 40 to 70 years. Sixty participants will be randomized in a double-blind, parallel-arm study to receive one of four doses of trigonelline monohydrate (equivalent to 150 mg, 300 mg, 450 mg, or 600 mg of trigonelline daily), an active comparator (600 mg nicotinamide mononucleotide \[NMN\]), or placebo for 4 weeks. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
Not yet recruitingNCT06889142
Impact of NMN Supplementation on CD4+ T Cell Recovery in HIV Patients With Immunological Failure
No phase
TriHealth Inc.
About 7 people
Starts Apr 2025 (estimated)
In plain words A study of NMN in people 18 and older, run by TriHealth Inc.. It plans to enroll about 7 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Human Immunodeficiency Virus.
HIV-infected adults aged 18 years or older
Virologically suppressed on ART documented with two negative viral loads separated by at least 6 months
Confirmed diagnosis of immunological failure (CD4+ T cell count <350 cells/µL 2 years after effective ART initiation)
Willing to provide informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Mononucleotide
Registered summary
This proof-of-concept study aims to investigate the potential impact of supplementing with Nicotinamide Mononucleotide (NMN), a direct precursor of NAD+ on CD4+ T cell recovery in virologically suppressed HIV patients experiencing immunological failure on ART. We hypothesize that NMN supplementation will increase intracellular NAD+ levels, thereby improving CD4+ T cell function and potentially reversing immunological failure. The full summary is on the listing.